• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety of dupilumab in atopic patients during COVID-19 outbreak.

作者信息

Napolitano Maddalena, Patruno Cataldo, Ruggiero Angelo, Nocerino Mariateresa, Fabbrocini Gabriella

机构信息

Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

出版信息

J Dermatolog Treat. 2022 Feb;33(1):600-601. doi: 10.1080/09546634.2020.1771257. Epub 2020 Jun 19.

DOI:10.1080/09546634.2020.1771257
PMID:32419563
Abstract
摘要

相似文献

1
Safety of dupilumab in atopic patients during COVID-19 outbreak.在新冠疫情期间度普利尤单抗在特应性患者中的安全性。
J Dermatolog Treat. 2022 Feb;33(1):600-601. doi: 10.1080/09546634.2020.1771257. Epub 2020 Jun 19.
2
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.青少年特应性皮炎：在意大利新冠疫情期间16周真实临床实践中使用度普利尤单抗的有效性和安全性
Dermatol Ther. 2021 Sep;34(5):e15035. doi: 10.1111/dth.15035. Epub 2021 Jun 25.
3
The impact of dupilumab treatment on SARS-CoV-2 T cell responses in atopic dermatitis patients.度普利尤单抗治疗对特应性皮炎患者严重急性呼吸综合征冠状病毒2（SARS-CoV-2）T细胞反应的影响。
Allergy. 2023 Feb;78(2):571-574. doi: 10.1111/all.15540. Epub 2022 Oct 17.
4
Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.在多伦多大学两所学术医院诊所的新冠疫情期间，患者驱动的度普利尤单抗停药情况
J Cutan Med Surg. 2020 Jul/Aug;24(4):422-423. doi: 10.1177/1203475420930223. Epub 2020 May 20.
5
Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study.度普利尤单抗治疗的特应性疾病患者中COVID-19的发病率和预后：一项多中心回顾性队列研究
J Dermatolog Treat. 2022 Aug;33(5):2692-2694. doi: 10.1080/09546634.2022.2036673. Epub 2022 Apr 21.
6
Dupilumab and COVID-19: What should we expect?度普利尤单抗与 COVID-19：我们应该期待什么？
Dermatol Ther. 2020 Jul;33(4):e13502. doi: 10.1111/dth.13502. Epub 2020 May 20.
7
Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.托珠单抗用于新型冠状病毒肺炎的理论依据与证据：一项系统评价。作者回复
Pulmonology. 2021 Jan-Feb;27(1):87-88. doi: 10.1016/j.pulmoe.2020.10.003. Epub 2020 Oct 21.
8
Safety of dupilumab in patients with atopic dermatitis: expert opinion.治疗特应性皮炎患者的度普利尤单抗的安全性：专家意见。
Expert Opin Drug Saf. 2021 Sep;20(9):997-1004. doi: 10.1080/14740338.2021.1939673. Epub 2021 Jun 19.
9
Young HIV-positive male patient with severe atopic dermatitis on dupilumab and SARS-CoV-2 infection, a pioneer hypothesis.一名感染严重特应性皮炎的HIV阳性年轻男性患者使用度普利尤单抗及感染了SARS-CoV-2，一个初步假设。
Int J Dermatol. 2021 Apr;60(4):514-515. doi: 10.1111/ijd.15499. Epub 2021 Feb 28.
10
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.

引用本文的文献

1
Advancements in acne detection: application of the CenterNet network in smart dermatology.痤疮检测的进展：CenterNet网络在智能皮肤病学中的应用。
Front Med (Lausanne). 2024 Mar 25;11:1344314. doi: 10.3389/fmed.2024.1344314. eCollection 2024.
2
Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review.2019年冠状病毒病大流行对特应性皮炎和食物过敏的成人及儿童的影响：系统评价
J Allergy Clin Immunol Glob. 2023 Oct 18;3(1):100181. doi: 10.1016/j.jacig.2023.100181. eCollection 2024 Feb.
3
Dermatologists' Perceptions of the Use of Teledermatology in Managing Hidradenitis Suppurativa: Survey Study.
皮肤科医生对使用远程皮肤病学管理化脓性汗腺炎的看法：调查研究
JMIR Dermatol. 2023 Jan 31;6:e43910. doi: 10.2196/43910.
4
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.慢性化脓性汗腺炎并发高级别鳞状细胞癌，使用西米普利单抗成功治疗：一例报告
Case Rep Dermatol. 2023 Feb 14;15(1):35-39. doi: 10.1159/000525347. eCollection 2023 Jan-Dec.
5
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.抗白细胞介素 23 生物制剂治疗银屑病：真实世界经验与临床试验数据对比。
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
6
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review.远程皮肤病学在2019年冠状病毒病大流行期间的作用：一项叙述性综述
Clin Cosmet Investig Dermatol. 2022 Dec 19;15:2785-2793. doi: 10.2147/CCID.S377029. eCollection 2022.
7
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗银屑病的真实世界证据综述
Clin Cosmet Investig Dermatol. 2022 Aug 16;15:1649-1658. doi: 10.2147/CCID.S364640. eCollection 2022.
8
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.古塞库单抗治疗中度至重度银屑病的长期疗效和安全性：一项3年真实世界回顾性研究
Psoriasis (Auckl). 2022 Jul 14;12:205-212. doi: 10.2147/PTT.S372262. eCollection 2022.
9
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.依奇珠单抗与布罗达单抗治疗中重度银屑病的间接比较：一项意大利单中心真实世界回顾性研究的结果
Dermatol Ther. 2022 Sep;35(9):e15667. doi: 10.1111/dth.15667. Epub 2022 Jul 11.
10
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.用于治疗银屑病的比美吉珠单抗：当前知识综述
Psoriasis (Auckl). 2022 Jun 8;12:127-137. doi: 10.2147/PTT.S367744. eCollection 2022.